Which Ketamine Routes Require In-Clinic Supervision?

Which Ketamine Routes Need In-Clinic Supervision?

Intravenous (IV) infusion, intramuscular (IM) injection, and esketamine (Spravato) nasal spray are the three ketamine delivery routes that require supervision in a clinical setting. Esketamine's supervision rule comes from a legally binding FDA Risk Evaluation and Mitigation Strategy (REMS) program. IV and IM ketamine aren't bound by that same federal mandate, but clinical standard of care calls for continuous monitoring because of dissociation, blood pressure changes, and sedation risk. Sublingual lozenges and some at-home intranasal protocols don't carry the same requirement, though many prescribers still observe a patient's first dose.

Why These Routes Carry a Supervision Requirement

Ketamine is a dissociative anesthetic that works mainly by blocking the N-methyl-D-aspartate (NMDA) receptor, a glutamate receptor involved in mood regulation and pain signaling. At doses used for depression or pain, it reliably produces dissociation (a feeling of detachment from your body or surroundings), temporary increases in blood pressure and heart rate, and sometimes nausea or dizziness. IV and IM administration deliver the drug quickly and reach a high peak concentration in the blood, which is why clinics check vital signs before, during, and after dosing. You can compare how quickly each route takes effect in our guide to ketamine onset time by route of administration, and how blood levels differ by route in our breakdown of peak plasma concentration ketamine by route.

Esketamine (Spravato): A Regulatory Requirement, Not Just a Clinical Preference

Esketamine (Spravato) is the only ketamine-based medicine with FDA approval, specifically for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder who have suicidal thoughts. Because of its REMS program, the FDA requires every dose to be given in a certified healthcare setting, administered by or under the direct observation of a health care provider, with the patient monitored for at least two hours afterward before being allowed to leave. Patients are also told not to drive themselves home the day of treatment. Our explainer on Spravato REMS requirements explained covers the full checklist certified clinics follow.

Generic (racemic) ketamine, by contrast, is prescribed off-label, meaning the FDA hasn't evaluated or approved it specifically for depression, anxiety, or other mental health uses. That off-label status means no federal REMS applies to IV, IM, sublingual, or intranasal generic ketamine. Supervision decisions for those routes are left to the prescriber, the clinic's own protocol, and, in a growing number of states, state-level rules for ketamine clinics.

Routes That Typically Don't Require In-Clinic Supervision

Sublingual and oral ketamine lozenges or troches are the routes most often prescribed for take-home use, usually through a telehealth-based program after an initial in-person or observed virtual visit. Buccal administration, where the lozenge is held against the cheek rather than swallowed, works on the same principle; see our guide to buccal ketamine administration, absorption, and clinical use for how it's typically dosed. Subcutaneous injections and some compounded intranasal formulations appear in both in-clinic and at-home protocols depending on the prescribing clinic; our guide to subcutaneous ketamine administration clinical use covers how that route is usually managed.

At-home prescribing doesn't mean unsupervised in an absolute sense. Clinics that compound their own ketamine or dispense through a pharmacy are expected to follow sourcing, dosing, and monitoring standards described in our overview of compounded ketamine safety oversight, and most require a telehealth check-in before and after each dose.